Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Melanoma 11Uveal Melanoma 3Skin Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Glioblastoma 2Carcinoma, Renal Cell 2Urologic Neoplasms 1Prostatic Neoplasms 1Neoplasms by Site 1Myelodysplastic Syndromes 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Gliosarcoma 1Eye Neoplasms 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Temozolomide 154Bevacizumab 88Radiotherapy 75Radiation 23Magnetic Resonance Spectroscopy 23Lomustine 18Irinotecan 18pembrolizumab 17Surgical Procedures, Operative 16Carmustine 16Erlotinib Hydrochloride 12Nivolumab 11Specimen Handling 10Aminolevulinic Acid 10sargramostim 9Thalidomide 9Chemotherapy, Adjuvant 9Carboplatin 9Drug Therapy 8Immunoglobulin G 7Filgrastim 7Etoposide 7Disulfides 7Cilengitide 7Sunitinib 6Sorafenib 6O(6)-benzylguanine 6Cyclophosphamide 6antineoplaston AS 2-1 5antineoplaston A10 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Glioblastoma × montanide ISA 51 × Clear all
NCT02455557 2026-03-30

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Roswell Park Cancer Institute

Phase 2 Active not recruiting
66 enrolled 11 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT04013672 2024-08-28

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Case Comprehensive Cancer Center

Phase 2 Completed
41 enrolled 15 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡